IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

PFIZER INC., C.P. PHARMACEUTICALS INTERNATIONAL C.V., PF PRISM C.V., PBG PUERTO RICO LLC, and PF PRISM IMB B.V.,	)	
Plaintiffs,	)	
v.	)	C.A. No. _____
SINOTHERAPEUTICS INC.,	)	
Defendant	)	

COMPLAINT

Pfizer Inc., C.P. Pharmaceuticals International C.V., PF PRISM C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. (collectively "Plaintiffs" or "Pfizer"), for their Complaint against Sinotherapeutics Inc. ("Defendant" or "Sinotherapeutics"), allege as follows:

NATURE OF THE ACTION

1. This is an action by Pfizer against Sinotherapeutics for infringement of United States Patent No. 9,937,181 ("the '181 patent").

2. This action arises out of Sinotherapeutics' filing of Abbreviated New Drug Application ("ANDA") No. 216001, seeking approval by the United States Food and Drug Administration ("FDA") to sell generic copies of Pfizer's 11 mg Xeljanz® XR (tofacitinib citrate extended-release tablets) prior to the expiration of the '181 patent. Sinotherapeutics' proposed 11 mg extended-release tofacitinib citrate product is referred to hereinafter as "Sinotherapeutics Generic XR Tablets."

THE PARTIES

3. Plaintiff Pfizer Inc. is a corporation organized and existing under the laws of the state of Delaware and having a place of business at 235 East 42nd Street, New York, New York 10017.

4. Plaintiff C.P. Pharmaceuticals International C.V. is a limited partnership (*commanditaire vennootschap*) organized under the laws of the Netherlands, having its business address at Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, the Netherlands. Pfizer Inc. is the ultimate parent company of C.P. Pharmaceuticals International C.V.

5. Plaintiff PF PRISM C.V. is a limited partnership (*commanditaire vennootschap*) organized under the laws of the Netherlands, having its registered seat in Rotterdam, the Netherlands, having its business address at Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, the Netherlands, and registered at the Trade Register held by the Chamber of Commerce in Rotterdam, the Netherlands, under number 51840456. Pfizer Inc. is the ultimate parent company of PF PRISM C.V.

6. Plaintiff PBG Puerto Rico LLC is a limited liability company organized and existing under the laws of Puerto Rico and having its business address at Professional Offices Park V, 996 San Roberto Street, 4th Floor, San Juan, Puerto Rico 00926. Pfizer Inc. is the ultimate parent company of PBG Puerto Rico LLC.

7. Plaintiff PF PRISM IMB B.V. is a private limited liability company (*besloten vennootschap*) under the laws of the Netherlands, having its registered seat in Rotterdam, the Netherlands, and having its business address at Rivium Westlaan 142, 2909 LD, Capelle aan den IJssel, the Netherlands. Pfizer Inc. is the ultimate parent company of PF PRISM IMB B.V.

8. On information and belief, defendant Sinotherapeutics Inc. is a company organized and existing under the laws of China, having its principal place of business at 99 Haike Road, Bldg. 3, First Floor, Pudong New District, Shanghai 201210, China.

JURISDICTION AND VENUE

9. This action arises under the patent laws of the United States, Title 35, United States Code. The Court has subject matter jurisdiction over this action pursuant to the provisions of 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

10. This Court has personal jurisdiction over Sinotherapeutics.

11. This Court has personal jurisdiction over Sinotherapeutics by virtue of the fact that, *inter alia*, Sinotherapeutics has committed a tortious act of patent infringement that has led and/or will lead to foreseeable harm and injury to Pfizer throughout the United States, including in the State of Delaware. In particular, this suit arises out of Sinotherapeutics' filing of ANDA No. 216001 seeking FDA approval to sell Sinotherapeutics Generic XR Tablets prior to the expiration of the '181 patent throughout the United States, including in the State of Delaware.

12. On information and belief, if ANDA No. 216001 is approved, Sinotherapeutics Generic XR Tablets will, among other things, be marketed and distributed by Sinotherapeutics in the State of Delaware, prescribed by physicians practicing in the State of Delaware, dispensed by pharmacies located within the State of Delaware, and/or used by patients in the State of Delaware.

13. Sinotherapeutics' infringing activities with respect to its filing of ANDA No. 216001 and its intent to commercialize and sell Sinotherapeutics Generic XR Tablets prior to the expiration of the '181 patent have led and/or will lead to foreseeable harm and injury to Pfizer, which is incorporated in Delaware.

14. In the alternative, this Court has personal jurisdiction over Sinotherapeutics under Federal Rule of Civil Procedure 4(k)(2). Sinotherapeutics has contacts with the United States by virtue, *inter alia*, of its filing ANDA No. 216001 with the FDA.

15. Venue is proper in this judicial district pursuant to 28 U.S.C. § 1391. As a foreign corporation, Sinotherapeutics may be sued in any judicial district pursuant to 28 U.S.C. § 1391(c)(3).

BACKGROUND

Xeljanz XR

16. The active ingredient in Pfizer's Xeljanz XR product is tofacitinib citrate. Xeljanz XR contains tofacitinib citrate in an amount equivalent to 11 mg of tofacitinib base in extended-release tablets formulated for once-daily administration.

17. The FDA-approved Prescribing Information for Xeljanz XR states that tofacitinib citrate has the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1).

18. Tofacitinib citrate is an inhibitor of Janus kinases ("JAKs") and is indicated, *inter alia*, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs ("DMARDs"), and for the treatment of adult patients with moderately to severely active ulcerative colitis who have an inadequate response or who are intolerant to TNF blockers.

Orange Book Listing for Xeljanz XR

19. Pfizer Inc. holds approved New Drug Application ("NDA") No. 208246 for, *inter alia*, EQ 11 mg base tofacitinib citrate extended-release tablets, which it sells under the registered name Xeljanz XR. The 11 mg Xeljanz XR tablets are approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

20. Pursuant to 21 U.S.C. § 355(b)(1) and the regulations the FDA has promulgated pursuant thereto, the '181 patent is listed in the FDA publication titled "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book") for the Xeljanz XR NDA.

21. The Orange Book lists the expiration date for the '181 patent as March 14, 2034.

22. The Orange Book lists two additional patents for the 11 mg strength of Xeljanz XR that are not at issue: U.S. Patent No. 6,965,027 (expiring March 25, 2023) and U.S. Patent No. RE41,783 (expiring December 8, 2025).

The '181 Patent

23. On April 10, 2018, the United States Patent and Trademark Office ("USPTO") issued the '181 patent, titled "Tofacitinib Oral Sustained Release Dosage Forms." The '181 patent is duly and legally assigned to Pfizer Inc. A copy of the '181 patent is attached hereto as Exhibit A.

24. C.P. Pharmaceuticals International C.V. is the exclusive licensee of the '181 patent.

25. C.P. Pharmaceuticals International C.V. conveyed rights under the '181 patent to Pfizer Pharmaceuticals LLC, PF PRISM C.V., and Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V.

26. Pfizer Pharmaceuticals LLC has conveyed its rights to the '181 patent to PBG Puerto Rico LLC.

27. Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V. has conveyed its rights to the '181 patent to PF PRISM IMB B.V.

Sinotherapeutics' ANDA

28. By letter dated August 20, 2021 (the "Sinotherapeutics Notice Letter"), and received by Pfizer on August 23, 2021, Sinotherapeutics notified Pfizer that it had submitted ANDA No. 216001 to the FDA, seeking approval under the Federal Food, Drug and Cosmetic Act to market and sell Sinotherapeutics Generic XR Tablets – generic copies of Xeljanz XR (tofacitinib citrate EQ 11 mg base extended-release tablets) – prior to the expiration of the '181 patent.

29. The Sinotherapeutics Notice Letter describes the Sinotherapeutics Generic XR Tablets as "extended release oral tablets containing 11 mg of tofacitinib citrate."

30. The Sinotherapeutics Notice Letter states that Sinotherapeutics has filed ANDA No. 216001 to obtain "approval from the FDA to market and sell" Sinotherapeutics Generic XR Tablets prior to the expiration of the '181 patent.

31. The Sinotherapeutics Notice Letter asserts that ANDA No. 216001 contains a "Paragraph IV" certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) and 21 C.F.R. § 314.94(a)(12)(i)(A)(4) alleging that Sinotherapeutics "will not infringe the claims of the '181 [p]atent by the manufacture, use, sale, offer to sell in the United States or importation into the United States of" Sinotherapeutics Generic XR Tablets.

32. Attached to the Sinotherapeutics Notice Letter was Sinotherapeutics' "Detailed Factual and Legal Basis for Sinotherapeutics Inc.'s Tofacitinib Citrate EQ 11 mg Base Extended Release Oral Tablets U.S. Patent No. 9,937,181" ("Sinotherapeutics' Detailed Statement") asserting the purported factual and legal bases for Sinotherapeutics' contention that the claims of the '181 patent will not be infringed, literally or under the doctrine of equivalents, by the commercial manufacture, use, sale, or offer for sale in the United States or importation into the United States of Sinotherapeutics Generic XR Tablets.

33. Sinotherapeutics' Detailed Statement alleges, *inter alia*, that Sinotherapeutics does not infringe any claim of the '181 patent, either literally or under the doctrine of equivalents.

34. Sinotherapeutics' Detailed Statement does not set forth an invalidity argument with respect to any claim of the '181 patent.

35. On information and belief, upon approval of ANDA No. 216001, Sinotherapuetics will sell and distribute Sinotherapeutics Generic XR Tablets in the United States.

CLAIM FOR RELIEF

(Infringement of the '181 Patent by Sinotherapeutics Generic XR Tablets)

36. The allegations of paragraphs 1-35 above are repeated and re-alleged as if set forth fully herein.

37. Pursuant to 35 U.S.C. § 271(e)(2)(A), Sinotherapeutics' filing of ANDA No. 216001 seeking approval to market and sell Sinotherapeutics Generic XR Tablets before the expiration of the '181 patent was an act of infringement, either literally or through the doctrine of equivalents, of at least claim 1 of the '181 patent, entitling Pfizer to the relief provided by 35 U.S.C. § 271(e)(4), including, *inter alia*, an order of this Court that the effective date of approval for ANDA No. 216001 be a date which is not earlier than the expiration date of the '181 patent.

38. Sinotherapeutics had knowledge of the '181 patent when it submitted ANDA No. 216001 to the FDA.

39. On information and belief, upon FDA approval of ANDA No 216001, Sinotherapeutics intends to engage in the manufacture, use, offer for sale, sale, and/or importation of Sinotherapeutics Generic XR Tablets into the United States and will thereby directly infringe, either literally or through the doctrine of equivalents, at least claim 1 of the '181 patent under 35 U.S.C. § 271(a).

40. The foregoing actions by Sinotherapeutics constitute and/or would constitute infringement of at least claim 1 of the '181 patent.

41. An actual controversy exists relating to Sinotherapeutics' threatened direct infringement of the '181 patent.

42. Pfizer will be substantially and irreparably harmed if Sinotherapeutics is not enjoined from infringing the '181 patent. Pfizer has no adequate remedy at law.

PRAYER FOR RELIEF

WHEREFORE, Pfizer requests the following relief:

A. A judgment that Sinotherapeutics' submission of ANDA No. 216001 was an act of infringement, either literally or through the doctrine of equivalents, of at least claim 1 of the '181 patent and that Sinotherapeutics' making, using, offering to sell, selling, or importing Sinotherapeutics Generic XR Tablets into the United States prior to the expiration of the '181 patent will directly infringe, either literally or through the doctrine of equivalents, at least claim 1 of the '181 patent;

B. A judgment that the effective date of any FDA approval for Sinotherapeutics to make, use, offer for sale, sell, market, distribute, or import Sinotherapeutics Generic XR Tablets into the United States be no earlier than the date on which the '181 patent expires, or the later expiration of any exclusivity to which Pfizer is or becomes entitled;

C. A permanent injunction enjoining Sinotherapeutics, its officers, agents, servants, and employees, and those persons in active concert or participation with any of them, from making, using, selling, offering for sale, marketing, distributing, or importing Sinotherapeutics Generic XR Tablets into the United States, and from inducing or contributing to any of the foregoing, prior to the expiration of the '181

patent, or the later expiration of any exclusivity to which Pfizer is or becomes entitled;

D. A judgment that this case is an exceptional case under 35 U.S.C. § 285, entitling Pfizer to an award of its reasonable attorneys' fees for bringing and prosecuting this action;

E. An award of Pfizer's costs and expenses in this action; and

F. Such further and additional relief as this Court deems just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Megan E. Dellinger

Jack B. Blumenfeld (#1014)
Megan E. Dellinger (#5739)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
mdellinger@morrisnichols.com

Attorneys for Plaintiffs

OF COUNSEL:

Aaron Stiefel
Daniel P. DiNapoli
Stephanie Piper
Michael Sapiro
ARNOLD & PORTER KAYE SCHOLER LLP
250 West 55th Street
New York, NY 10019-9710
(212) 836-8000

Soumitra Deka
DLA PIPER LLP (US)
555 Mission Street, Suite 2400
San Francisco, CA 94105-2933
(415) 836-2500

October 6, 2021